Core Viewpoint - Aibono Medical has announced its entry into the sports medicine sector by acquiring a 68.31% stake in Demai Medical for 683 million yuan, utilizing a combination of acquisition loans and its own funds [1] Group 1: Acquisition Details - The acquisition of Demai Medical, established in 2016, is characterized by a high premium, with a valuation of 1.074 billion yuan, representing a 343.29% increase over its net asset value of 242 million yuan [2] - Demai Medical is recognized for its comprehensive product line in sports health, covering pre-surgery prevention, surgical treatment, and post-surgery rehabilitation, and has been included in the national high-value medical consumables procurement list [2] Group 2: Financial Performance - Aibono Medical reported a revenue of 1.41 billion yuan in 2024, a year-on-year increase of 48.22%, with a net profit of 387 million yuan, up 27.36% [3] - However, the company faces challenges due to a 60% price drop in artificial lenses following the implementation of national procurement policies, leading to a decline in profit margins [3] Group 3: Challenges and Opportunities - The sports medicine sector presents significant potential but is becoming increasingly competitive, with both foreign and domestic players vying for market share [5] - Aibono Medical plans to launch new products to counteract the impact of procurement policies, including a new artificial lens and a corneal reshaping lens, although these may not fully offset the profit decline from the artificial lens business [5] Group 4: Market Response - Following the announcement of the acquisition, Aibono Medical's stock price rose by 2.36%, reaching 62.4 yuan per share, with a total market capitalization of 12.068 billion yuan [6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 一次性使用超聲乳化玻切沖洗吸引管路套件獲得 中國醫療器械註冊證 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 高視醫療科技有限公司 主席兼執行董事 高鐵塔先生 香港，2025年7月14日 截至本公告日期，董事會包括主席兼執行董事高鐵塔先生，執行董事劉新偉先生、趙新禮先 生、張建軍先生及李文奇女士，非執行董事David Guowei Wang博士，以及獨立非執行董事馮 昕先生、王立新先生及陳帆城先生。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司附屬公司深圳高視科技 ...